HealthDay - Cymbalta Approved for Fibromyalgia
Eli Lilly said Monday that its antidepressant Cymbalta (duloxetine) has been approved by the U.S. Food and Drug Administration to treat fibromyalgia, a chronic disorder with symptoms including widespread muscle pain and tenderness.
The condition affects about 2 percent of the American population, or about 5 million people, mostly women. While its cause is unknown and there is no known cure, it’s believed it may be related to a combination of changes in brain and spinal cord chemistry, genetic factors, and stress, the company said in a statement.
Most Popular
5 Regular Mistakes In Public Speaking
SWOT Analysis - To Make Your Business More Profitable
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
Cymbalta affects production of two naturally occurring brain substances, serotonin and norepinephrine. In …
Read the full article with a Free Trial at MyWire.
